The companies will jointly develop and commercialize Lenvima as monotherapy and in combination with Merck’s Keytruda for multiple cancer types.
Related Biotechnology, Pharmaceutical and Healthcare News
Contributed Author:
Merck & Co. and Eisai Co., Ltd
